ARTICLE | Clinical News
Tenofovir disoproxil fumarate: Phase III started
July 25, 2005 7:00 AM UTC
GILD began the double-blind, international, Phase III Study 102 trial in about 300 patients with HBeAg-negative/anti-HBe positive chronic HBV. In the trial 200 patients will receive 300 mg once-daily ...